Cardiac Science (NASDAQ:DFIB)
Historical Stock Chart
From Jul 2019 to Jul 2024
Cardiac Science Awarded Contract With Novation
Group Purchasing Organization Serves 2,300 Healthcare Facilities Nationwide
IRVINE, Calif., March 30 /PRNewswire-FirstCall/ -- Cardiac Science, Inc.
(NASDAQ:DFIB), a leading manufacturer of automatic external defibrillators,
today announced that it has been awarded a contract from Novation, the supply
company of VHA Inc. and the University HealthSystem Consortium (UHC), covering
Cardiac Science's patented Powerheart(R) Cardiac Rhythm Module(R) (CRM(R)) a
fully-automatic therapeutic bedside monitor-defibrillator designed for
medically-supervised environments such as hospitals, outpatient medical clinics
and physician offices. The contract, which was established under Novation's
new technology program, offers access to this innovative product to 2,300 VHA
and UHC acute and non-acute healthcare facilities located throughout the United
States.
Powerheart CRM is the only FDA-cleared therapeutic bedside defibrillator-
monitor on the market that is designed to be prophylactically attached to
at-risk cardiac patients, continuously monitor their heart rhythms and when
clinically appropriate, automatically and instantly provide lifesaving
defibrillation therapy without the need to wait for intervention by a nurse or
physician.
Cardiac Science Chairman and CEO Raymond W. Cohen said, "The Novation contract
provides us with access to a large group of hospitals and increases awareness
of the Powerheart CRM technology among administrators and other decision
makers. As clinical evidence mounts that suggests this technology may
dramatically increase survival rates of at-risk cardiac patients and
potentially reduce hospitalization costs, we believe that we may achieve
greater penetration in the U.S. hospital market. "
About Novation
Based in Irving, Texas, Novation was established in January 1998 through a
combination of the supply programs of VHA and UHC, two national health care
alliances. Novation serves the purchasing needs of more than 2,300 members and
affiliates of VHA and UHC. These organizations used Novation contracts to
purchase more than $23 billion in supplies in 2004.
About Cardiac Science
Cardiac Science develops, manufactures and markets a complete line of
Powerheart(R) brand, automated public access defibrillators (AEDs), and offers
comprehensive AED/CPR training and AED program management services that
facilitate successful deployments. The company makes the Powerheart(R) CRM(R),
the only FDA-cleared therapeutic patient monitor that instantly and
automatically treats hospitalized cardiac patients who suffer life-threatening
heart rhythms. Cardiac Science also manufactures its AED products on a private
label basis for other leading medical companies such as Nihon Kohden (Japan),
Quinton Cardiology Systems and GE Healthcare. For more information please
visit http://www.cardiacscience.com/ or call (949) 797-3800.
This press release includes forward-looking statements. These statements may
be identified by the use of forward-looking terminology such as "anticipate,"
"believe," "continue," "could," "estimate," "expect," "intend," "may," "might,"
"plan," "potential," "predict," "should," or "will," or the negative thereof or
other variations thereon or comparable terminology. Cardiac Science has based
these forward-looking statements on the current expectations, assumptions,
estimates and projections. While Cardiac Science believes these expectations,
assumptions, estimates and projections are reasonable, such forward-looking
statements are only predictions and involve known and unknown risks and
uncertainties, many of which are beyond our control. Certain factors,
including those discussed in Cardiac Sciences' Annual Report on Form 10-K for
the year ended December 31, 2004, under the heading "Risk Factors," may cause
the actual results, performance or achievements to differ materially from any
future results, performance or achievements expressed or implied by these
forward-looking statements. Given these risks and uncertainties, you are
cautioned not to place undue reliance on such forward-looking statements. We
do not undertake any obligation to update any such statements or to publicly
announce the results of any revisions to any such statements to reflect future
events or developments.
Contact:
Matt Clawson (Investors), or Michael Gioffredi
Len Hall (Media) Chief Marketing Officer
Allen & Caron Inc Cardiac Science, Inc.
(949) 474-4300 (949) 797-3800
DATASOURCE: Cardiac Science, Inc.
CONTACT: Investors, Matt Clawson, , or Media, Len
Hall, , both of Allen & Caron Inc, +1-949-474-4300, for
Cardiac Science, Inc.; or Michael Gioffredi, Chief Marketing Officer of
Cardiac Science, Inc., +1-949-797-3800,
Web site: http://www.cardiacscience.com/